Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 286 posts found.

BMS image

BMS sells diabetes stake to partner AstraZeneca

December 19, 2013
Sales and Marketing AstraZeneca, BMS, Forxiga, Onglyza, diabetes, komboglyze

AstraZeneca will buy out Bristol-Myers Squibb’s stake in its diabetes alliance in a potential $4.3 billion deal. AZ will pay …

News
screen_shot_2013-12-16_at_07

BMS appoints Thomas Lynch to board

December 16, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, lynch

Bristol-Myers Squibb has elected Thomas Lynch to its board to serve as a member on its Science and Technology Committee …

Appointment
giovanni-caforio-2011-2

Several leadership changes at Bristol-Myers Squibb

November 18, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS

BMS has made several modifications to its senior management team with appointments and role shuffles being the order of the …

Appointment
BMS image

BMS abandons hep C, diabetes and neuroscience

November 11, 2013
Sales and Marketing BMS, HIV, diabetes, hep C

Bristol-Myers Squibb is admitting defeat in hepatitis C, diabetes and neuroscience and will abandon research in these areas in a …

News
BMS image

BMS files oral hep C treatment

November 5, 2013
Sales and Marketing BMS, HCV, dvc, hep C

Bristol-Myers Squibb has filed its investigational hepatitis C treatment – the first oral regime without interferon or ribavirin – with …

News
bms

Yervoy setback in prostate cancer

September 16, 2013
Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer

News
GSK image

GSK cancer vaccine fails in Phase III

September 5, 2013
Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III

GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …

News
Tafinlar image

GSK’s skin cancer pill Tafinlar gets EMA approval

September 3, 2013
Sales and Marketing BMS, GSK, Tafinlar, Yervoy, melanoma

GSK has been granted EMA marketing authorisation for its new metastatic melanoma drug Tafinlar. The EMA’s decision on Tafinlar (dabrafenib) …

News
samsung image

BMS taps Samsung for antibody manufacturing

July 30, 2013
Manufacturing and Production BMS, Samsung, antibody

Bristol-Myers Squibb has given signed a 10-year contract with South Korea’s Samsung BioLogics for the manufacture of one of its …

News
Forxiga image

AZ and BMS go for second Forxiga submission

July 29, 2013
Sales and Marketing AZ, BMS, FDA, Forxiga

AstraZeneca and partner Bristol-Myers Squibb have resubmitted their diabetes drug Forxiga to the FDA 18 months after it was rejected …

News
BMS image

Sharp fall in sales for Bristol-Myers Squibb

July 26, 2013
Sales and Marketing Avapro, BMS, Plavix, Q2

Bristol-Myers Squibb has seen a fall in sales over the past three months as it struggles with major patent losses. …

News
pfizer image

NICE rejects Pfizer blood cancer drug

July 16, 2013
Sales and Marketing BMS, CML, NICE, Pfizer, bosulif

NICE is not recommending Pfizer’s blood cancer drug Bosulif due to uncertainties over its cost effectiveness and survival benefit. In …

News
Eliquis image

Eliquis poised for new US approval

July 12, 2013
Sales and Marketing BMS, Bayer, DVT, Eliquis, warfarin

Pfizer and Bristol-Myers Squibb have submitted their oral direct Factor Xa inhibitor Eliquis to the FDA to prevent deep vein …

News
eliquis image

VTE boost for Eliquis

July 2, 2013
Research and Development, Sales and Marketing AMPLIFY, BMS, DVT, Eliquis, Pfizer

Bristol-Myers Squibb and Pfizer’s oral blood thinner Eliquis is as efficient as standard of care and causes less bleeding in …

News
Forxiga image

NICE completes Forxiga U-turn

June 26, 2013
Sales and Marketing BMS, Forxiga, NICE

Bristol-Myers Squibb and AstraZeneca are celebrating after NICE reversed its decision from earlier this year and is now recommending their …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026